Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 270 participants, all of whom received nivolumab at a dose of 3 mg/kg. The trial was measuring how often the treatment caused tumours to shrink or disappear (called the "objective response rate"), how long participants lived without their cancer getting worse ("progression-free survival"), and how long participants lived overall ("overall survival"). The trial also looked at whether a protein called PD-L1 — found on some cancer cells — affected any of these results. None of the 270 participants were recorded as having completed the study in the usual sense, as all 270 were listed under "not completed," which likely reflects that follow-up was ongoing or participants had left the study for various reasons before a formal completion point. The reported data shows that, as assessed by an independent review panel, about 19.6% of all participants had their tumours shrink or disappear to a meaningful degree. When broken down by PD-L1 levels, the reported response rates ranged from approximately 15.8% to 28.4% depending on the subgroup. When the treating doctors made their own assessments, the reported response rate across all participants was 24.8%, with subgroup figures ranging from roughly 19.9% to 33.7%. The reported median time until cancer stopped getting worse (progression-free survival) was around 1.87 to 3.68 months depending on the group measured, and the reported median overall survival ranged from approximately 5.95 to 13.54 months across the different subgroups. The median time from first dose until a response was first recorded was reported as approximately 1.97 months. It is important to note that these figures are summaries of what was recorded and submitted to a public registry — they describe what was measured in this specific group of trial participants under the conditions of the study. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 28131785) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Bladder Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have bladder cancer or cancer of the urinary tract (such as the urethra, ureter, or kidney's drainage system) that has spread to other parts of the body or cannot be removed by surgery
- Your cancer can be measured on a CT or MRI scan
- Your cancer has come back or gotten worse after previous treatment
- You have previously been treated with at least one chemotherapy regimen containing platinum (such as cisplatin or carboplatin) for advanced or spread cancer, OR your cancer came back within 12 months of receiving platinum-based chemotherapy before or after surgery to remove the bladder
- If you have received more than two rounds of chemotherapy in the past, your cancer must not have spread to the liver
- You are able to provide a tissue sample from your tumor — either from a previous biopsy or a new one — for research testing
- You are generally healthy and able to carry out daily activities with little or no difficulty (confirm with trial site)
Who may not be able to join:
- Your cancer has spread to the brain or spinal cord
- You have had another type of cancer in the last 3 years, unless it was a slow-growing, localised cancer that appears to have been fully treated
- You have an active autoimmune disease (a condition where your immune system attacks your own body)
- You are currently taking steroid medicines (above a low dose) or other medications that suppress your immune system
- You have previously been treated with certain immunotherapy drugs that work by targeting specific immune system pathways (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 treatments)
- You currently have, or have had, an active hepatitis B or hepatitis C infection shown by a blood test
- You have tested positive for HIV or have been diagnosed with AIDS
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Objective Response Rate Per BIRC Assessment; ORR Per BIRC Assessment by PD-L1 Expression Level; Time to Response (TTR); Duration of Response (DOR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.